≡

Multiplex Assay Kit for Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay)

PlGF2; PGF; PGFL; Placental Growth Factor-Like; Vascular Endothelial Growth Factor-Related Protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 87-105 96
EDTA plasma(n=5) 78-91 85
heparin plasma(n=5) 94-102 98

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 93-102% 85-92% 91-105% 80-96%
EDTA plasma(n=5) 82-98% 90-98% 79-93% 86-93%
heparin plasma(n=5) 98-105% 82-96% 96-105% 95-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PLGF) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Microvascular Research Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle PubMed: 20937289
Oncogene Elevated PLGF contributes to small-cell lung cancer brain metastasis PubMed: 22797069
?eLife Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 PubMed: PMC3687373
International Journal of Nanomedicine Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis Pubmed:27042064
The Journal of Maternal-Fetal & Neonatal Medicine Serum angiogenic profile in abnormal placentation Pubmed:26863111
Fertility and Sterility Administration of atosiban in patients with endometriosis undergoing frozen–thawed embryo transfer: a prospective, randomized study Pubmed:27143518
Basic & Clinical Pharmacology & Toxicology Placental Growth Factor Triggers Epithelial-to-Mesenchymal Transition-like Changes in Rat Type II Alveolar Epithelial Cells: Activation of Nuclear Factor κB Signalling Pathway doi:10.1111
Life Sci. Placenta growth factor contributes to cell apoptosis and epithelial-to-mesenchymal transition in the hyperoxia-induced acute lung injury Pubmed:27211521
Int Immunopharmacol Knockdown of placental growth factor (PLGF) mitigates hyperoxia-induced acute lung injury in neonatal rats: Suppressive effects on NFκB signaling pathway Pubmed:27280587
Journal of Maternal-Fetal & Neonatal Medicine Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus Pubmed: 30935303
Children (Basel) sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates 34438609
Dose-Response: An International Journal Puerarin Reduces Radiation-Induced Vascular Endothelial Cell Damage Via miR-34a/Placental Growth Factor Pubmed:35110976
Catalog No. Related products for research use of Bos taurus; Bovine (Cattle) Organism species Applications (RESEARCH USE ONLY!)
RPA114Bo01 Recombinant Placenta Growth Factor (PLGF) Positive Control; Immunogen; SDS-PAGE; WB.
PAA114Bo01 Polyclonal Antibody to Placenta Growth Factor (PLGF) WB; IHC; ICC; IP.
SEA114Bo ELISA Kit for Placenta Growth Factor (PLGF) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA114Bo Multiplex Assay Kit for Placenta Growth Factor (PLGF) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.